Related Experiment Videos
Generalized osteoblastic bony metastases from medulloblastoma
Oncology
|January 1, 1976
Summary
Medulloblastoma can cause osteoblastic bone metastases years after treatment. This case showed a positive response to COP therapy, with increased bone density and alkaline phosphatase, despite normal calcitonin levels.
Area of Science:
- Oncology
- Bone Metabolism
- Pediatric Oncology
Background:
- Medulloblastoma is a common pediatric brain tumor.
- Bone metastases are rare in medulloblastoma survivors.
- Long-term surveillance is crucial for detecting late complications.
Observation:
- A patient with medulloblastoma developed osteoblastic bone metastases 3 years post-treatment.
- Clinical and radiographic evidence of bone metastases was observed.
- The patient received COP (cytoxin, oncovin, prednisone) therapy.
Findings:
- COP therapy led to clinical improvement and increased bone density on scans.
- Elevated alkaline phosphatase normalized with treatment, suggesting bone deposition.
- Serum calcium, phosphorous, and acid phosphatase remained normal.
- Calcitonin levels were not elevated during active disease or remission.
Implications:
- Osteoblastic metastases can occur late after medulloblastoma treatment.
- COP therapy may be effective for managing these metastases.
- Alkaline phosphatase may indicate bone turnover activity.
- Calcitonin is not a reliable biomarker for this condition in medulloblastoma.